Our ultimate vision is to prevent and provide cures for cancer in all its forms. As no single intervention is likely to achieve this, we seek to comprehensively understand the disease, its complexities and its impact on patients. By giving our researchers the freedom to explore the cutting edge of science and technology, we deepen our understanding of the biology and immunology of cancer to make this vision a reality sooner.
Cancer: from one disease to many
Historically, cancer was treated as a single disease, but we now know that there are more than 200 different types,1 each with different behaviours, rates of growth and stages of progression. This has triggered a shift away from a ‘one-size-fits-all’ treatment approach (e.g. chemotherapy) towards tailored therapy and personalised healthcare.2
Advances in molecular and genomic sciences have helped to break new ground in personalised healthcare for cancer,3 particularly in the development of new medicines and diagnostics.4 With technical innovations such as next-generation sequencing and liquid biopsy, we are pioneering a new era in cancer diagnostics to improve the lives of cancer patients across the care continuum. Combination therapies, which use a number of treatments at once (for example targeted therapies and immunotherapy), or one after another to attack and kill cancer cells in different ways, are also showing great promise for cancer patients.5
Continued R&D investment is needed to increase our understanding of cancer
We have made great strides in our understanding of cancer, but more needs to be done. It is estimated that from 2012 to 2035 there will be a 70% increase in the number of new cancer cases6 and a 75% increase in cancer-related deaths per year.
We will do all we can to help combat this by continuing to invest heavily in research, by focusing on unpicking the science behind cancer, by collaborating closely with all our partners, and by developing innovative diagnostics and medicines.
“We recognise the importance of this investment and we are the only major pharmaceutical company to spend more on R&D than marketing,” said Dietmar Berger, Global Head of Oncology Product Development. “The impact our work has had on society has been profound and we are committed to continuing our work until we have achieved our goal – helping society to overcome the challenge of cancer.”
To date, our cancer medicines have U.S. Food and Drug Administration (FDA) breakthrough designations eight times, highlighting their potential importance.12
The future outlook; tackling the ever increasing burden of cancer
Several cancer types and subtypes remain stubbornly difficult to treat and major inequalities still exist in terms of outcomes.13 This, tied with our growing and ageing population, and new and emerging factors (diet, environment, exposure, etc.), constitute an ever-increasing burden on society.14
We have a R&D pipeline that we believe will make a significant difference to people with cancer and to the wider oncology landscape.
Ban katantaWith our leading Pharmaceuticals and Diagnostics businesses under one roof, we are better positioned to deliver personalised healthcare than any other company. An exchange of know-how and intellectual property, combined with our breadth of diagnostic technologies, allows us to identify patient subsets that are suitable for clinical trials, and predict and monitor treatment responses. Our diagnostic strength spans various cancers including breast, cervical, colon, lung, prostate, melanoma and ovarian.
Ban katantaOvercoming cancer’s destructive potential will require a mix of incremental progress and giant leaps forward, and we are proud to be leading the way.
See below for examples of how we are driving the science in oncology:
Ban katanta1. Cancer Research UK. Last accessed February 2017.
2. F. Hoffmann-La Roche Ltd. Progress in cancer. Ban katantaLast accessed February 2017.
3. Vucic E, et al. Genome Res. 2012;22(2):188-95.
4. Ciardiello F, et al. Ann Oncol. 2014;25(9):1673-78.
5. Li F, et al. Int J Cancer. 2014;134(6):1257-69.
6. World Health Organization. . Last accessed February 2017.
7. F. Hoffmann-La Roche Ltd. Roche 2016 Annual Report. Last accessed February 2017.
8. F. Hoffmann-La Roche Ltd. Roche outlines oncology partnering program. Last accessed February 2017.
9. F. Hoffmann-La Roche Ltd. From molecule to medicine. Ban katantaLast accessed February 2017.
10. F. Hoffman-La Roche Ltd. Half year 2016 results presentation. Last accessed February 2017.
Ban katanta11. Data on file.
Ban katanta12. Friends of Cancer Research. . Last accessed February 2017.
13. International Prevention Research Institute. The state of oncology 2013. Last accessed February 2017.
14. Jemal A, et al. CA Cancer J Clin.Ban katanta 2011;61(2):69-90.
15. F. Hoffmann-La Roche Ltd. YTD September 2016 presentation. Last accessed February 2017.